Companies › Urotronic
1 active drug program in 1 registered trial: 1 Phase 4; Genitourinary; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Optilume Urethral DCB Paclitaxel-coated balloon catheter | Tubulin | Phase 4 | Urethral Stricture | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05383274 | Optilume Urethral DCB | Phase 4 | Urethral Stricture | Genitourinary | Jun 2027 |
Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Beijing Biostar Pharmaceuticals Ambrx
Prokidney YolTech Therapeutics Cisen Pharmaceutical Levee Medical Vensica Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.